T1	Participants 600 630	patients with first-line NSCLC
T2	Participants 674 813	patients with locally advanced or metastatic NSCLC who were eligible for bevacizumab, excluding those with predominantly squamous histology
T3	Participants 1167 1202	1967 patients with first-line NSCLC
T4	Participants 1274 1311	Median age was 65 years (range, 31-93
T5	Participants 1318 1366	252 patients (12.8%) identified as never smokers
T6	Participants 1879 1928	real-world patient population with advanced NSCLC
